About: Gynecologic Oncology Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gynecologic Oncology Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

non-profit organization

Attributes	Values
rdf:type	Item
field of work	wds:Q5625184-E1314532-77CE-46E6-AC8F-AFEA2296FD2B
field of work	gynecologic oncology
owl:sameAs	Gynecologic Oncology Group
description	amerikanische Non-Profit-Organisation (de) американська неприбуткова організація (uk) non-profit organization (en)
rdfs:label	Gynecologic Oncology Group (en) جمعية الأورام النسائية (ar) ഗൈനക്കോളജിക്കൽ ഓങ്കോളജി ഗ്രൂപ്പ് (ml)
skos:prefLabel	Gynecologic Oncology Group (en) جمعية الأورام النسائية (ar) ഗൈനക്കോളജിക്കൽ ഓങ്കോളജി ഗ്രൂപ്പ് (ml)
name	Gynecologic Oncology Group (en) جمعية الأورام النسائية (ar) ഗൈനക്കോളജിക്കൽ ഓങ്കോളജി ഗ്രൂപ്പ് (ml)
Freebase ID	wds:Q5625184-3A8A680D-C25A-40EB-AD29-B3C38870E8E2
Freebase ID	/m/04xk3j
ROR ID	wds:Q5625184-4C9222A5-8139-46F8-8AEA-B6B5192A3260
ROR ID	04x187e69
instance of	wds:Q5625184-4ccea0db-447a-b785-e500-3158ec9b9769 wds:Q5625184-c81b261c-4fe8-2556-d186-b2a43b0ed966
instance of	nonprofit organization medical organization
country	wds:Q5625184-7fa8f672-41ef-fea8-000a-4271ef670776
country	United States of America
Ringgold ID	wds:Q5625184-2A1947D0-13E8-4107-8AB9-552E6296DAB5
Ringgold ID	2067
skos:altLabel	GOG Foundation (en)
located in the adm...erritorial entity	wds:Q5625184-70E74604-B6AE-4339-8F1D-AA25C2EB307E
X username	wds:Q5625184-F3BF99A1-0F95-4FD6-8E50-0BF295FE467E
Facebook username	wds:Q5625184-9B25F70B-33F4-40E7-AAC1-9A5486AB23B2
ISNI	wds:Q5625184-84D5379E-3032-44E0-8930-B7152B054888
VIAF ID	wds:Q5625184-7867DD1E-831A-4EE7-8038-5BA9535EC5E7
Microsoft Academic ID	wds:Q5625184-C56ACC76-EC8A-4BE8-895C-83709A5814A7
WorldCat Identities ID (superseded)	wds:Q5625184-FFBC7C3A-7F8C-4114-9E82-680142B87244
official website	wds:Q5625184-9F4D7080-E5E7-4879-B48F-6810CEDEF740
sponsor	wds:Q5625184-E936FFA1-38BC-4731-B25B-2FFD5E3C346F
VIAF ID	http://viaf.org/viaf/187804337
Microsoft Academic ID	https://makg.org/entity/117693200
located in the adm...erritorial entity	Crofton
X username	gog
Facebook username	Saudi-Gynecology-Oncology-Group-SGOG-112595408820531
ISNI	0000000403823117
VIAF ID	187804337
Microsoft Academic ID	117693200
WorldCat Identities ID (superseded)	viaf-187804337
official website	http://www.gog.org/
sponsor	National Cancer Institute
GRID ID	wds:Q5625184-F29B6496-3750-4B28-BF7D-0E3841CB9DCD
GRID ID	grid.434982.0
is about of	Gynecologic Oncology Group https://www.wikidata.org/wiki/Special:EntityData/Q5625184 Gynecologic Oncology Group https://ar.wikipedia.org/wiki/%D8%AC%D9%85%D8%B9%D9%8A%D8%A9_%D8%A7%D9%84%D8%A3%D9%88%D8%B1%D8%A7%D9%85_%D8%A7%D9%84%D9%86%D8%B3%D8%A7%D8%A6%D9%8A%D8%A9 https://ml.wikipedia.org/wiki/%E0%B4%97%E0%B5%88%E0%B4%A8%E0%B4%95%E0%B5%8D%E0%B4%95%E0%B5%8B%E0%B4%B3%E0%B4%9C%E0%B4%BF%E0%B4%95%E0%B5%8D%E0%B4%95%E0%B5%BD_%E0%B4%93%E0%B4%99%E0%B5%8D%E0%B4%95%E0%B5%8B%E0%B4%B3%E0%B4%9C%E0%B4%BF_%E0%B4%97%E0%B5%8D%E0%B4%B0%E0%B5%82%E0%B4%AA%E0%B5%8D%E0%B4%AA%E0%B5%8D
is research site of	Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers Prognostic Biomarkers in Patients With Endometrial Cancer Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Biomarkers in Samples From Patients With Endometrial Cancer Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Research Study in Patients With Advanced Ovarian Epithelial Cancer Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software